Physician profile
Jonathan H Phillips
NPI 1518937689
$398,087.32
in general payments reported to CMS, 2019-2025
5 companies · $80K in 2025
The $80K reported for 2025 was more than what 99% of Pediatric Orthopaedic Surgery providers received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73K · 2020: $37K · 2021: $55K · 2022: $2,162 · 2023: $75K · 2024: $75K · 2025: $80K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $220K · Consulting Fee: $9,600 · Travel and Lodging: $671 · Food and Beverage: $11.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $220,343.34 |
| Consulting Fee | $9,600.00 |
| Travel and Lodging | $670.71 |
| Food and Beverage | $11.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthopediatrics Corp. | $395,234.84 | 2019-2025 | |
| Zimmer Biomet Holdings, INC. | $2,479.66 | 2019-2021 | |
| Nuvasive, INC. | $141.22 | 2019 | |
| Medical Device Business Services, INC. | $122.70 | 2019 | |
| Nuvasive Specialized Orthopedics, INC. | $108.90 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.